Abstract
A-56268 was compared with erythromycin, roxithromycin (RU 28965), and perorally administered antimicrobial agents. Its in vitro activity was similar to that of erythromycin and slightly greater than that of roxithromycin, with beta-hemolytic streptococci and Streptococcus pneumoniae inhibited by less than 2 micrograms of A-56268 per ml (50% inhibited by 0.06 microgram/ml). Streptococcus pyogenes, S. agalactiae, S. Pneumoniae, and S. faecalis resistant to erythromycin were resistant to A-56268, and 4 micrograms/ml inhibited 90% of Haemophilus influenzae isolates.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barlam T., Neu H. C. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Apr;25(4):529–531. doi: 10.1128/aac.25.4.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L., Thornsberry C. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother. 1983 Aug;24(2):209–215. doi: 10.1128/aac.24.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosenblatt J. E., Schoenknecht F. Effect of several components of anaerobic incubation on antibiotic susceptibility test results. Antimicrob Agents Chemother. 1972 May;1(5):433–440. doi: 10.1128/aac.1.5.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Washington J. A., 2nd, Wilson W. R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). Mayo Clin Proc. 1985 Apr;60(4):271–278. doi: 10.1016/s0025-6196(12)60322-x. [DOI] [PubMed] [Google Scholar]